Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-10-22-Speech-3-157"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20081022.17.3-157"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, I would like to thank you for giving me the floor and I would also like to thank Mrs Grossetête for the report on the proposed directive, which deals with variations to the terms of marketing authorisations for medicinal products. I supported it in the vote. It represents progress in the harmonisation of laws and in consumer protection, reducing bureaucracy, increasing flexibility and bringing benefits in terms of the safety and awareness of patients. At the same time, it simplifies operations and reduces costs for medium-sized pharmaceutical firms.
I appreciate the clear stand taken by Commissioner Verheugen over counterfeit drugs, low-quality generic drugs that often have no more effect than a placebo and illicit drugs and vaccines, which find their way to European citizens via the black market. Such activities are criminal. In the near future, the Commission will draw up measures to strengthen existing laws in this area so that none of these drugs may be distributed. It will also introduce sanctions against persons operating in this area. The Commissioner has also ensured that effective drugs must be produced on the basis of recognised European standards and manufacturing processes."@en1
|
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples